JP7657727B2 - 抗原性多量体呼吸器合胞体ウイルスポリペプチド - Google Patents

抗原性多量体呼吸器合胞体ウイルスポリペプチド Download PDF

Info

Publication number
JP7657727B2
JP7657727B2 JP2021558831A JP2021558831A JP7657727B2 JP 7657727 B2 JP7657727 B2 JP 7657727B2 JP 2021558831 A JP2021558831 A JP 2021558831A JP 2021558831 A JP2021558831 A JP 2021558831A JP 7657727 B2 JP7657727 B2 JP 7657727B2
Authority
JP
Japan
Prior art keywords
rsv
polypeptide
gcc
antigenic
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021558831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525431A (ja
JP2022525431A5 (enExample
Inventor
カート・スワンソン
チー－ジェン・ウェイ
ゲイリー・ジェイ・ネーベル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2022525431A publication Critical patent/JP2022525431A/ja
Publication of JP2022525431A5 publication Critical patent/JP2022525431A5/ja
Priority to JP2025003856A priority Critical patent/JP2025063151A/ja
Application granted granted Critical
Publication of JP7657727B2 publication Critical patent/JP7657727B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021558831A 2019-04-02 2020-04-01 抗原性多量体呼吸器合胞体ウイルスポリペプチド Active JP7657727B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025003856A JP2025063151A (ja) 2019-04-02 2025-01-10 抗原性多量体呼吸器合胞体ウイルスポリペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962828302P 2019-04-02 2019-04-02
US62/828,302 2019-04-02
PCT/US2020/026198 WO2020205986A1 (en) 2019-04-02 2020-04-01 Antigenic multimeric respiratory syncytial virus polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025003856A Division JP2025063151A (ja) 2019-04-02 2025-01-10 抗原性多量体呼吸器合胞体ウイルスポリペプチド

Publications (3)

Publication Number Publication Date
JP2022525431A JP2022525431A (ja) 2022-05-13
JP2022525431A5 JP2022525431A5 (enExample) 2024-07-12
JP7657727B2 true JP7657727B2 (ja) 2025-04-07

Family

ID=70465435

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558831A Active JP7657727B2 (ja) 2019-04-02 2020-04-01 抗原性多量体呼吸器合胞体ウイルスポリペプチド
JP2025003856A Pending JP2025063151A (ja) 2019-04-02 2025-01-10 抗原性多量体呼吸器合胞体ウイルスポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025003856A Pending JP2025063151A (ja) 2019-04-02 2025-01-10 抗原性多量体呼吸器合胞体ウイルスポリペプチド

Country Status (5)

Country Link
US (1) US12454553B2 (enExample)
EP (1) EP3946446A1 (enExample)
JP (2) JP7657727B2 (enExample)
CN (2) CN114957407A (enExample)
WO (1) WO2020205986A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114957407A (zh) * 2019-04-02 2022-08-30 赛诺菲 抗原性多聚呼吸道合胞病毒多肽
US11608458B2 (en) 2019-12-19 2023-03-21 Prc-Desoto International, Inc. Adhesion-promoting interlayer compositions containing organic titanates/zirconates and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000512136A (ja) 1996-06-05 2000-09-19 バイオモレキュラー・リサーチ・インスティテュート・リミテッド 呼吸器合胞体ウイルスのｇタンパク質と構造的ホモロジーを有するウイルス性ペプチド
WO2019032480A1 (en) 2017-08-07 2019-02-14 Avatar Medical, Llc PROTEINS F PRE-FUSION OF RSV STABILIZED IN TERMS OF CONFORMATION

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0777685B1 (en) * 1994-08-25 1999-04-14 Stichting Instituut voor Dierhouderij en Diergezondheid Antigenic peptides derived from the g protein of rsv for type- and subtype-specific diagnosis of respiratory syncytial virus (rsv) infection
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
KR100938105B1 (ko) * 2007-09-21 2010-01-21 이화여자대학교 산학협력단 호흡기 신시치아 바이러스 백신
WO2010075491A2 (en) * 2008-12-24 2010-07-01 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
US9060975B2 (en) * 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
US9703095B2 (en) 2015-01-05 2017-07-11 Edward Pakhchyan Light modulator for MEMS display
WO2016160166A1 (en) * 2015-03-30 2016-10-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic rsv polypeptides
EA201891000A1 (ru) * 2015-10-22 2018-12-28 МОДЕРНАТиЭкс, ИНК. Вакцина против респираторно-синцитиального вируса
BR112018076015A8 (pt) 2016-06-17 2022-06-28 Sanofi Pasteur Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado .
WO2018154010A1 (en) * 2017-02-23 2018-08-30 Alpha-O Peptides Ag Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids
CN111344008A (zh) * 2017-09-15 2020-06-26 俄亥俄州创新基金会 用于预防呼吸道合胞病毒(rsv)感染的疫苗及其制备和使用方法
EP3773698A1 (en) * 2018-04-03 2021-02-17 Sanofi Ferritin proteins
CN114957407A (zh) 2019-04-02 2022-08-30 赛诺菲 抗原性多聚呼吸道合胞病毒多肽

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000512136A (ja) 1996-06-05 2000-09-19 バイオモレキュラー・リサーチ・インスティテュート・リミテッド 呼吸器合胞体ウイルスのｇタンパク質と構造的ホモロジーを有するウイルス性ペプチド
WO2019032480A1 (en) 2017-08-07 2019-02-14 Avatar Medical, Llc PROTEINS F PRE-FUSION OF RSV STABILIZED IN TERMS OF CONFORMATION

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Immunology Letters，2016年，179，pp.95-101
PLoS ONE，2017年，12(4):e0175384，pp.1-19
Vaccine，2010年，28， pp.6242-6246

Also Published As

Publication number Publication date
JP2025063151A (ja) 2025-04-15
JP2022525431A (ja) 2022-05-13
EP3946446A1 (en) 2022-02-09
US20220119457A1 (en) 2022-04-21
WO2020205986A1 (en) 2020-10-08
US12454553B2 (en) 2025-10-28
CN114269373A (zh) 2022-04-01
CN114957407A (zh) 2022-08-30

Similar Documents

Publication Publication Date Title
JP7614841B2 (ja) 抗原性呼吸器合胞体ウイルスポリペプチド
CA3146464C (en) Antigen specific immunotherapy employing covid-19 fusion proteins and methods of use
KR102252163B1 (ko) 인플루엔자 바이러스 백신 및 그의 용도
CN112638411B (zh) 疫苗组合物
JP2025063151A (ja) 抗原性多量体呼吸器合胞体ウイルスポリペプチド
KR20220010478A (ko) 기도 감염의 치료 또는 예방용 서브유닛 백신
KR102777000B1 (ko) 인플루엔자 바이러스 백신 및 이의 용도
CN105792842A (zh) 埃巴病毒疫苗
US11806394B2 (en) Protein-based nanoparticle vaccine for metapneumovirus
US20230399364A1 (en) Immunogenic Coronavirus Fusion Proteins and Related Methods
CN113227123A (zh) 重组呼吸道合胞病毒f蛋白以及包含该蛋白的疫苗组合物
WO2022011021A1 (en) Use of conserved peptide epitopes from sars-cov-2 for the development of a broad covid-19 vaccine
US12397050B2 (en) Universal mammalian influenza vaccine
KR102765237B1 (ko) Rsv의 f 단백질-항체 복합체 및 이를 포함하는 조성물
JP2024502823A (ja) 安定なコロナウィルスタンパク質およびそのワクチン組成物
CN118176204A (zh) 截短的流感神经氨酸酶及其使用方法
CN117377679A (zh) 抗病毒感染的胜肽疫苗
RU2807992C2 (ru) Антигенные полипептиды на основе последовательности респираторно-синцитиального вируса
RU2811991C2 (ru) Субъединичная вакцина для лечения или предотвращения инфекции дыхательных путей
WO2026033489A1 (en) Chimeric fusion proteins as respiratory syncytial virus (rsv) vaccines
CN117177774A (zh) Sars-cov-2受体结合结构域与载体蛋白的共价缀合物以及包含它们的疫苗组合物
EA048316B1 (ru) Ковалентные конъюгаты рецептор-связывающего домена sars-cov-2 и белка-носителя и содержащие их вакцинные композиции
CA2886189A1 (en) Polypeptides and their use in treating metapneumovirus (mpv) infection
WO2023020637A1 (es) Antigenos quimericos para el control de coronavirus y composiciones que los comprenden
EA052740B1 (ru) Иммуногенные слитые белки коронавируса и связанные с ними способы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230303

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240612

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250326

R150 Certificate of patent or registration of utility model

Ref document number: 7657727

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150